

# Phytochemical, Free Radical Scavenging and Cytotoxic Assay of *Cucumis Melo* L. Extract and $\beta$ -Carotene

Wahyu Widowati

Maranatha Christian University, Faculty of Medicine, Bandung, Indonesia

Email: wahyu\_w60@yahoo.com

Rachma Micho Widyanto, Dian Ratih Laksmiawati, Pande Putu Erawijantari, Laura Wijaya, and Ferry Sandra

Faculty of Agricultural Technology, Brawijaya University, Malang, Indonesia

Faculty of Pharmacy, Pancasila University, Jakarta, Indonesia

Biomolecular and Biomedical Research Center, Aretha Medika Utama, Bandung, Indonesia

Stem Cell and Cancer Institute, Jakarta, Indonesia

Faculty of Dentistry, Trisakti University, Jakarta, Indonesia

Email: {rahmamicho, dianratih.ffup, erawijantari, a.c.laura.w}@gmail.com, ferrysandra@yahoo.com

**Abstract**—Deaths from cancer worldwide are estimated to continue rising. Free radicals are toxic to cellular components. It is known that they cause DNA damage, contribute to DNA instability and mutation, thus favor carcinogenesis. This research was conducted to determine the activity of *Cucumis melo* extract and  $\beta$ -carotene in antioxidative and cytotoxic potencies. The research was done by examining the 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging activity assay. The cytotoxic potency was determined by the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay on HeLa, HepG2 and NIH3T3 cell lines.  $\beta$ -carotene exhibited more active DPPH free radical scavenging activity compared with *C. melo* extract. *C. melo* extract showed more active anti-cancer both in HeLa (IC<sub>50</sub>: 23.649  $\mu$ g/mL) and HepG2 (IC<sub>50</sub>: 110.403  $\mu$ g/mL) cancer cells. *C. melo* extract (IC<sub>50</sub>: 16,670.404  $\mu$ g/mL) and  $\beta$ -carotene (IC<sub>50</sub>: 50,645.994  $\mu$ g/mL) had low cytotoxicity in NIH3T3 fibroblast. *C. melo* extract has lower antioxidant activity, but higher cytotoxic potency compared with  $\beta$ -carotene.

**Index Terms**—antioxidant, free radical, melon, *cucumis melo*,  $\beta$ -carotene, cancer, cytotoxic.

## I. INTRODUCTION

As the world major public health problem, cancer-related deaths are projected to continue rising [1], [2], with an estimation of 12 million deaths per year expected by 2030 [3]. More than 700,000 new cancer cases per year occur in ASEAN countries, which is also expected to increase [4]. Cancer has a severe impact on individual and community, it leads to disability and death, with high-cost therapy [1], [5]. Cancer therapies include surgery [6], chemotherapy [7], radiotherapy [8], immunotherapy [9] and gene therapy [10], could have

unwelcome side-effects [1], and possibly low cure rates [11].

Free radicals can cause DNA damage, instability and mutation, leading to damage of cellular components and/or carcinogenesis [3]. It has been reported that several anti-cancer substances inhibit free radical production and oxidative DNA damage, hence inhibit tumor promotion [12].

There has been growing interest using herbs as new anti-cancer drugs. Plants contain a wide variety of chemicals that have potent biological effects, including anti-cancer activity [13]. Large number of plants and pure isolated compounds contain potential anti-cancer activity [14]. The cucurbitacins provide great interest due to its various bioactivities [1]. Meanwhile muskmelons contain high vitamin A, vitamin C [15] and  $\beta$ -carotene [16], [17].

In this research, we performed determination of the phytochemical constituents of california cantaloupe or *Cucumis melo* L. (*C. melo*) extract, evaluation of 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging potency of *C. melo* extract and major constituent of  $\beta$ -carotene, and evaluation of cytotoxic potency of *C. melo* extract and  $\beta$ -carotene in HeLa, HepG2 and NIH3T3 cell lines.

## II. MATERIAL AND METHOD

### A. Preparation of Extract

Five hundred grams of *C. melo* were purchased from traditional market located in Caringin, West Java, Indonesia. The fruits were washed with distilled water, ground and soaked in 70% destilated ethanol. After 24 hours, filtrate was collected and residue was soaked again in 70% ethanol for another 24 hours. These treatments were repeated until the filtrate became colorless. The

filtrate was evaporated with a rotary evaporator at 40 °C yielding 24.5 g extract. The extracts were stored at 4 °C [18], [19].

### B. Phytochemical Assay

*C. melo* extract was tested with phytochemical assay using modified Farnsworth method for flavonoid, phenolic, saponin, triterpenoid, steroid, terpenoid, tannin and alkaloid [20].

### C. DPPH Free Radical Scavenging Activity Assay

Fifty µl *C. melo* extract and β-carotene (Sigma-Aldrich, St. Louis, MO) were introduced into a microplate followed by 200 µl of 0.077 mmol/l DPPH solution (Sigma-Aldrich). The mixtures was shaken vigorously and kept in the dark for 30 minutes at room temperature. DPPH free radical scavenging activity was determined with a microplate reader at 517 nm [18], [19]. The DPPH free radical scavenging activity of each sample was measured according to (1)

$$\text{Scavenging \%} = (Ac - As) / Ac \times 100. \quad (1)$$

As: sample absorbance

Ac: negative control absorbance (without sample)

### D. Cytotoxic Assay

HeLa human cervical cancer cell line, HepG2 liver cancer cell line, NIH3T3 mouse fibroblast were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich), 100 U/mL penicillin (Sigma-Aldrich), and 100 µg/mL streptomycin (Sigma-Aldrich). Cells were incubated at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub> [18], [19], [21]. After the cells reached 80% confluency, 5,000 cells were seeded in each well of 96-well plate. After 24 hours incubation, the cells were treated with *C. melo* extract or β-carotene at various concentrations (0, 1, 10, 100, 1000 µg/mL) for 24 hours. To determine cell viability, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega, Madison, WI, USA) was used. MTS was added to each well at a ratio of 1:5. The plate was incubated in 5% CO<sub>2</sub> at 37 °C for 4 hours. Absorbance was measured at 490 nm on a microplate reader. The data were presented as number of cells, the percentage of viable cells (%), inhibition proliferation of growth cells (%). The data were analyzed using ANOVA

and continued by Tukey post hoc test. We also calculated the median inhibitory concentration (IC<sub>50</sub>) using Probit Analysis of IBM SPSS Statistics for Windows, Version 20 (IBM Corp., Armonk, NY, USA) [22].

## III. RESULT

### A. Phytochemical Result

The phytochemical assay showed that extract of *C. melo* contained low terpenoids, tannins and phenols content (Table I)

### B. DPPH Free Radical Scavenging Activity

DPPH free radical scavenging activity of the sample was marked by color change from dark purple to yellowish or pale yellow [21]. The DPPH free radical scavenging activity of *C. melo* extract or β-carotene was increased significantly in a concentration dependent manner (Table II). By adding higher concentration of *C. melo* extract or β-carotene, higher DPPH activity was obtained. Compared with *C. melo* extract, β-carotene showed higher DPPH activity.

### C. Cytotoxic Activity

Number of viable HeLa and HepG2 cancer cells were decreased significantly in *C. melo* extract and β-carotene concentration dependent manners (Table III). By adding higher concentration of *C. melo* extract or β-carotene, lower number of viable cancer cell was obtained. Meanwhile, NIH3T3 cells were also decreased in *C. melo* extract and β-carotene concentration dependent manners, but not significant. The data of viable cancer cell number were then converted into percentage of viable cancer cell as shown in Table IV, so that the effect of *C. melo* extract and β-carotene on the cells could be demonstrated clearly. In order to describe percentage of growth inhibition effect of *C. melo* extract and β-carotene on cancer cells, data shown in Table III were converted into Table V.

Concentration that could inhibit 50% cell growth (IC<sub>50</sub>) of *C. melo* extract and β-carotene was calculated and shown in Table VI. Growth inhibition data in Table V were analyzed using probit analysis to obtain the IC<sub>50</sub>. Both *C. melo* extract and β-carotene were not toxic in NIH3T3 cells since the calculated IC<sub>50</sub> showed very high concentration.

TABLE I. THE RESULT OF PHYTOCHEMICAL ASSAY OF *C. MELO* EXTRACT

Sample	Compound content							
	Tannins	Triterpenoids	Steroids	Terpenoids	Saponins	Alkaloids	Flavonoids	Phenols
<i>C. melo</i> extract	+	-	-	+	-	-	+	+

Additional information

++++ : very high content

+++ : high content

++ : moderate content

+: low content

- : undetected

TABLE II. DPPH FREE RADICAL SCAVENGING ACTIVITY OF *C. MELO* EXTRACT AND BETA-CAROTENE.

Samples	Concentration (µg/mL)						
	100	50	25	12.5	6.25	3.125	1.563
β-carotene	73.10±1.53 <sup>f</sup>	55.23±3.03 <sup>e</sup>	44.72±2.08 <sup>d</sup>	32.45±3.26 <sup>c</sup>	19.59±2.06 <sup>b</sup>	15.62±0.62 <sup>ab</sup>	12.49±0.94 <sup>a</sup>
<i>C. melo</i> extract	38.38±3.48 <sup>e</sup>	32.71±1.26 <sup>d</sup>	23.52±0.88 <sup>c</sup>	11.60±0.53 <sup>b</sup>	4.75±0.44 <sup>a</sup>	3.18±0.57 <sup>a</sup>	1.32±0.33 <sup>a</sup>

Data were presented as mean ± standard deviation. Different letters in the same row among concentrations of samples indicate significant differences (Tukey's HSD post hoc test). Each sample was performed in triplicate.

TABLE III. EFFECT *C. MELO* EXTRACT AND BETA-CAROTENE ON NUMBER OF CANCER CELL.

Samples	Concentration of treatment ( $\mu\text{g/mL}$ )				
	0	1	10	100	1000
<i>C. melo</i> extract					
HeLa	26,787 $\pm$ 90 <sup>e</sup>	16,250 $\pm$ 61 <sup>d</sup>	15,173 $\pm$ 45 <sup>c</sup>	12,443 $\pm$ 72 <sup>b</sup>	8,433 $\pm$ 32 <sup>a</sup>
HepG2	22,085 $\pm$ 260 <sup>e</sup>	17,317 $\pm$ 32 <sup>d</sup>	13,235 $\pm$ 132 <sup>c</sup>	12,008 $\pm$ 20 <sup>b</sup>	81,28 $\pm$ 10 <sup>a</sup>
NIH3T3	8,857 $\pm$ 244 <sup>c</sup>	8,863 $\pm$ 189 <sup>c</sup>	8,562 $\pm$ 85 <sup>c</sup>	7,837 $\pm$ 34 <sup>b</sup>	6,663 $\pm$ 105 <sup>a</sup>
$\beta$ -carotene					
HeLa	26,787 $\pm$ 90 <sup>e</sup>	18,697 $\pm$ 1,410 <sup>d</sup>	16,087 $\pm$ 176 <sup>c</sup>	11,637 $\pm$ 437 <sup>b</sup>	9,757 $\pm$ 151 <sup>a</sup>
HepG2	22,085 $\pm$ 260 <sup>e</sup>	17,272 $\pm$ 195 <sup>d</sup>	13,768 $\pm$ 161 <sup>c</sup>	13,188 $\pm$ 79 <sup>b</sup>	9.203 $\pm$ 53 <sup>a</sup>
NIH3T3	8,857 $\pm$ 244 <sup>d</sup>	8,558 $\pm$ 159 <sup>cd</sup>	8,195 $\pm$ 56 <sup>cd</sup>	7,581 $\pm$ 55 <sup>b</sup>	6,628 $\pm$ 59 <sup>a</sup>

Data were presented as mean  $\pm$  standard deviation. Different letters in the same row among concentrations of samples indicate significant differences (Tukey's HSD post hoc test). Each sample was performed in triplicate.

TABLE IV. EFFECT *C. MELO* EXTRACT AND BETA-CAROTENE ON PERCENTAGE OF VIABLE CANCER CELL.

Samples	Concentration of Treatment ( $\mu\text{g/mL}$ )				
	0	1	10	100	1000
<i>C. melo</i> extract					
HeLa	100.00 $\pm$ 0.33 <sup>e</sup>	60.66 $\pm$ 0.23 <sup>d</sup>	56.64 $\pm$ 0.17 <sup>c</sup>	46.45 $\pm$ 0.27 <sup>b</sup>	31.48 $\pm$ 0.12 <sup>a</sup>
HepG2	100.00 $\pm$ 1.18 <sup>e</sup>	78.41 $\pm$ 0.14 <sup>d</sup>	59.93 $\pm$ 0.60 <sup>c</sup>	54.37 $\pm$ 0.09 <sup>b</sup>	36.80 $\pm$ 0.05 <sup>a</sup>
NIH3T3	100.00 $\pm$ 2.75 <sup>c</sup>	100.07 $\pm$ 2.14 <sup>c</sup>	96.67 $\pm$ 0.97 <sup>c</sup>	88.48 $\pm$ 0.38 <sup>b</sup>	75.23 $\pm$ 1.19 <sup>a</sup>
$\beta$ -carotene					
HeLa	100.00 $\pm$ 0.33 <sup>e</sup>	69.80 $\pm$ 5.26 <sup>d</sup>	60.05 $\pm$ 0.66 <sup>c</sup>	43.44 $\pm$ 1.63 <sup>b</sup>	36.42 $\pm$ 0.57 <sup>a</sup>
HepG2	100.00 $\pm$ 1.18 <sup>e</sup>	78.21 $\pm$ 0.88 <sup>d</sup>	62.34 $\pm$ 0.73 <sup>c</sup>	59.72 $\pm$ 0.36 <sup>b</sup>	41.67 $\pm$ 0.24 <sup>a</sup>
NIH3T3	100.00 $\pm$ 2.75 <sup>d</sup>	100.07 $\pm$ 2.14 <sup>cd</sup>	96.67 $\pm$ 0.97 <sup>c</sup>	88.48 $\pm$ 0.38 <sup>b</sup>	75.23 $\pm$ 1.19 <sup>a</sup>

Data were presented as mean  $\pm$  standard deviation. Different letters in the same row among concentrations of samples indicate significant differences (Tukey's HSD post hoc test).

TABLE V. EFFECT *C. MELO* EXTRACT AND BETA-CAROTENE ON PERCENTAGE OF CANCER CELLS GROWTH INHIBITION.

Samples	Concentration of treatment ( $\mu\text{g/mL}$ )				
	0	1	10	100	1000
<i>C. melo</i> extract					
HeLa	0.00 <sup>a</sup>	39.34 <sup>b</sup>	43.36 <sup>c</sup>	53.55 <sup>d</sup>	68.52 <sup>e</sup>
HepG2	0.00 <sup>a</sup>	21.59 <sup>b</sup>	40.07 <sup>c</sup>	45.63 <sup>d</sup>	63.20 <sup>e</sup>
NIH3T3	0.00 <sup>a</sup>	-0.07 <sup>a</sup>	3.33 <sup>a</sup>	11.52 <sup>b</sup>	24.77 <sup>c</sup>
$\beta$ -carotene					
HeLa	0.00 <sup>a</sup>	30.20 <sup>b</sup>	39.95 <sup>c</sup>	56.56 <sup>d</sup>	63.58 <sup>e</sup>
HepG2	0.00 <sup>a</sup>	21.79 <sup>b</sup>	37.66 <sup>c</sup>	40.28 <sup>d</sup>	58.33 <sup>e</sup>
NIH3T3	0.00 <sup>a</sup>	3.37 <sup>ab</sup>	7.47 <sup>b</sup>	15.26 <sup>c</sup>	25.16 <sup>d</sup>

Data were presented as mean  $\pm$  standard deviation. Different letters in the same row among concentrations of samples indicate significant differences (Tukey's HSD post hoc test).

TABLE VI. THE IC<sub>50</sub> OF *C. MELO* EXTRACT AND B-CAROTENE IN VARIOUS CANCER CELL LINES IN 24 HOURS TREATMENT.

Cell Type	IC <sub>50</sub> ( $\mu\text{g/mL}$ )	
	$\beta$ -carotene	<i>C. melo</i> extract
HeLa	51.760	23.649
HepG2	270.419	110.403
NIH3T3	50,645.994	16,670.404

#### IV. DISCUSSION

Our phytochemical result showed that *C. melo* contained low phenols and flavonoids. Although previous study showed that aqueous of *C. melo* extract contained high alkaloids, and flavonoids [23], a recent study has shown also that *C. melo* contain low bioactive

constituents such as alkaloids and saponins [15]. The phenolic and flavonoid compounds in the plants could have various biological activity such as antioxidant activity [24], [25]. Meanwhile, activity of *C. melo* extract is particularly due to the presence of phenolic compounds especially flavonoids [26]. It has been reported that DPPH free radical scavenging activity increased along with increased concentration of *C. melo* extract and  $\beta$ -carotene [27]. We found DPPH free radical scavenging activity of 100  $\mu\text{g/mL}$  *C. melo* extract was 38.38%. It was lower compared with previous study reporting that the activity was 55% [27]. This might be related with the source of *C. melo*. Compared with fruit, it has been reported that high antioxidant activity was found in leaf and stem extracts of *C. melo* [26]. In addition, *C. melo* seed extract had 75.59% DPPH free radical scavenging

activity at concentration of 300 µg/mL [28]. DPPH free radical scavenging activity of β-carotene was high, this result was validated with previous study reporting that β-carotene has potential antioxidant biological properties due to its chemical structure. β-carotene quenches singlet oxygen with a multiple higher efficiency than α-tocopherol [29]. β-carotene has antioxidant properties, is a precursor of Vitamin A, and imparts the orange color in some fruits and vegetables. This compound is the major carotenoid in *C. melo* [17].

Our data showed that *C. melo* extract and β-carotene had cytotoxic potency on cancer cells. This result is in accordance with many previous studies as follows. β-carotene have anti-neoplastic effects in some individuals [30]. β-carotene can be used in prevention and treatment of many cancer cells [31]. β-carotene increased the cyclin-dependent kinase inhibitor p21<sup>WAF1/CIP1</sup> expression related with cell death [31]. β-carotene inhibited cell proliferation, arrested the cell cycle in different phases, and increased apoptosis. These findings indicate that the effect was cell type-dependent and that carotenoids are potential agents for biological interference with cancer [32].

Consumption of carotenoids is associated with reduced risk of chronic diseases, including cancer and vascular diseases [33]. β-carotene is associated with reduction in the risk of prostate cancer [34], HT-29 colon adenocarcinoma cancer cells [33] and AtT-20 mouse corticotroph tumor cell line [35]. β-carotene induced an increase of the cells in S and G2/M phases. β-carotene induced apoptosis, reduced expression of phosphorylated-Cx43 [35]. Carotenoids inhibited AtT-20 cell proliferation and colony formation, induced apoptosis and cell cycle arrest, and reduced adrenocorticotrophic hormone (ACTH) secretion [36].

*C. melo* extract showed anti-cancer activity, this result is in accordance with previous study showing that *C. melo* reduced hyperplasia of the prostate and induces apoptosis [37]. A common component in melons, 3-methylthiopropionic acid ethyl ester (MTPE), was first identified as a volatile constituent of *C. melo* [38]. MTPE treatment for 4 days in RCM-1 human colon cancer cell line increased alkaline phosphatase (ALP) activity, indicated that MTPE possess potential anti-carcinogenic properties by inducing differentiation [38].

Cucurbitacin B (CuB) and CuE, which are obtained from the calyx melo of *C. melo* [1], significantly inhibited the growth of tumor *in vivo* and *in vitro* in a dose-dependent manner. Many anti-cancer agents arrest the cell cycle at the G1, S, or G2/M phase and then induce apoptotic cell death [1]. CuB had a significant inhibitory effect on proliferation of cervical cancer (HeLa), hepatoma (HepG2) and murine sarcoma (S180) cells in a dose-dependent manner [1]. CuE demonstrated cytotoxic activity against malignant glioblastoma multiforme 8401 cells and induced cell cycle G2/M arrest in these cells [39]. CuB is a natural anti-cancer agent isolated from the stem of *C. melo*. CuB inhibits signal transducer and activator of transcription 3 (STAT3) activation and the Raf/MEK/ERK pathway in K562 leukemia cells. CuA

and CuE have significant anti-tumor activity [1], [26], [40]. In our current results, *C. melo* extract had more active cytotoxic potency compared with β-carotene, since *C. melo* constitutes many of potential compounds including β-carotene itself, CuA, CuB, CuE and MTPE, which each compound has anti-cancer activity.

In conclusion, *C. melo* extract has lower antioxidant activity, but higher cytotoxic potency compared with β-carotene in this *in vitro* study. Further mode of action test, preclinical and clinical studies should be pursued before pharmaceutical applications.

#### ACKNOWLEDGMENT

The authors acknowledge gratefully for the financial support from Ministry of Research and Technology, Republic of Indonesia (Research Grant no KP-2010-593) and support from Stem Cell and Cancer Institute, Jakarta.

#### REFERENCES

- [1] J. Wang, X. Zhou, Y. Cao, J. Xiao, E. Ma, Y. Deng, and D. Chen, "The antitumor activities of cucurbitacin liposome for injection both *in vitro* and *in vivo*," *Asian J. Trad Med*, vol. 2, no. 3, pp. 98-103, May 2007.
- [2] R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistic 2014," *CA Cancer J. Clin*, vol. 64, pp. 9-29, January/February 2014.
- [3] R. M. Sainz, F. Lombo, and J. C. Mayo, "Radical decisions in cancer: redox control of cell growth and death," *Cancers*, vol. 4, pp. 442-474, April 2012.
- [4] J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin DM, "Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008," *Int J. Cancer*, vol. 127, pp. 2893-2917, December 2010.
- [5] M. Kimman, R. Norman, S. Jan, D. Kingston, and M. Woodward, "The burden of cancer in member countries of the association of Southeast Asian Nations (ASEAN)," *Asian Pac J. Cancer Prev*, vol. 13, pp. 411-21, 2012.
- [6] J. Cummins and P. McCulloch, "ASCOT: A comprehensive clinical database for gastro-oesophageal cancer surgery," *Eur J. Surg Oncol*, 2001, vol. 27, pp. 709-713, December 2001.
- [7] N. Takiguchi, N. Saito, M. Nunomura, K. Kouda, K. Oda, N. Furuyama, *et al.*, "Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: Evaluation of antitumor effect and measurement of 5-FU in individual organs," *Cancer Chemother Pharmacol*, vol. 47, pp. 11-14, 2001.
- [8] G. I. Schmitt and A. Wambersie, "Review of the clinical results of fast neutron therapy," *Radiother Oncol*, vol. 17, pp. 47, January 2001.
- [9] T. Sharav, K. H. Wiesmüller, and P. Walden, "Mimotope vaccines for cancer immunotherapy," *Vaccine*, vol. 25, no. 16, pp. 3032-3037, April 2007.
- [10] M. G. Rots, D. T. Curiel, W. R. Gerritsen, and H. J. Haisma, "Targeted cancer gene therapy: The flexibility of adenoviral gene therapy vectors," *J Control Release*, vol. 87, pp. 159-165, February 2003.
- [11] G. M. Wilkes, "Therapeutic options in the management of colon cancer: 2005 update," *Clin J. Oncol Nurs*, vol. 9, pp. 31-44, February 2005.
- [12] J. M. Matés and F. M. Sánchez-Jiménez, "Role of reactive oxygen species in apoptosis: Implications for cancer therapy," *Int J. Biochem Cell Biol*, vol. 32, no. 2, pp. 157-70, February 2000.
- [13] M. B. Sporn and N. Suh, "Chemoprevention of cancer," *Carcinogenesis*, vol. 21, pp. 525-30, December 2000.
- [14] A. Patil, K. Vadera, D. Patil, A. Phatak, A. Juvekar, and N. Chandra, "In vitro anticancer activity of argemone mexicana l. seeds and alstonia scholaris (l.) r. br. bark on different human cancer cell lines," *World J. Pharm Pharmaceutical Sci*, vol. 3, no. 11, pp. 706-722, October 2014.
- [15] S. R. Kumar, S. Priyadarshini, K. P. L. Nandha Kumar, and S. Nivedha, "In vitro pharmacognostical studies and evaluation of

- bioactive constituents from the fruits of *Cucumis melo* L. (Muskmelon)," *Int J. Pharmacognosy Phytochem Res.*, vol. 6, no. 4, pp. 936-941, November 2014.
- [16] S. Hercberg, "The history of  $\beta$ -carotene and cancers: From observational to intervention studies. What lessons can be drawn for future research on polyphenols?" *Am J. Clin Nutr.*, vol. 81, pp. 218S-222S, 2005.
- [17] A. R. Davis, W. W. Fish, and P. Perkins-Veazie, "A rapid spectrophotometric method to determine  $\beta$ -Carotene content in cucumis melo germplasm," *Cucurbit Genetics Cooperative Report*, vol. 31-32, pp. 5-7, 2009.
- [18] W. Widowati, L. Wijaya, T. L. Wargasetia, I. Bachtiar, Y. Yellianty, and D. R. Laksmiawati, "Antioxidant, anticancer, and apoptosis-inducing effects of Piper extracts in HeLa cells," *J. Exp Integrat Med.*, vol. 3, no. 3, pp. 225-230, June 2013.
- [19] W. Widowati, T. Mozef, C. Risdian, and Y. Yellianty, "Anticancer and free radical scavenging potency of catharanthus roseus, dendrophthoe petandra, piper betle and curcuma mangga extracts in breast cancer cell lines," *Oxid Antioxid Med Sci.*, vol. 2, no. 2, pp. 137-142, April 2013b.
- [20] W. Widowati, H. Ratnawati, U. Rusdi, W. Winarno, and V. Immanuel, "Phytochemical assay and antiplatelet activity of fractions of velvet been seeds (*Mucuna pruriens* L.)," *Hayati J. Biosci.*, vol. 17, no. 2, pp. 85-90, June 2010.
- [21] E. Evacuasiy, H. Ratnawati, L. K. Liana, W. Widowati, M. Maesaroh, T. Mozef, and C. Risdian, "Cytotoxic and antioxidant activities of catechins in inhibiting the malignancy of breast cancer," *Oxid Antioxid Med Sci.*, vol. 3, no.2, pp. 141-146, June 2014.
- [22] W. Widowati, L. Wijaya, H. Murti, H. Widyastuti, D. Agustina, D. R. Laksmiawati, *et al.*, "Conditioned medium from normoxia (WJMScs-norCM) and hypoxia-treated WJMScs (WJMScs-hypoCM) in inhibiting cancer cell proliferation," *Biomarkers Genomic Med.*, vol. 20, pp. 1-10, January 2015.
- [23] S. P. Itiyavirah, A. George, A. M. Santhosh, S. D. Kurian, P. Pappachan, and G. Jacob, "Studies of cytotoxic potential of *Cucumis melo*. Linn fruit aqueous extract in prostate cancer cell lines PC-3 using MTT and neutral red assay," *Iranian J. Pharmacol Ther.*, vol. 12, no. 1, pp. 24-29, December 2013.
- [24] B. Halliwell, J. Rafter, and A. Jenner, "Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: Direct or indirect effects? Antioxidant or not?" *Am J. Clin Nutr.*, vol. 81, pp. 268S-76S, January 2005.
- [25] S. P. Wesley, C. B. Devi, S. Moin, and S. B. Shibu, "In vitro phytochemical screening, free radical scavenging activity and anticancer activity of abutilon hirtum (Lam.) Sweet (Malvaceae)," *Int J. Phram Tech Res.*, vol. 5, no. 1, pp. 155-161, March 2013.
- [26] P. Milind and S. Kulwant, "Musk melon is eat-must melon," *Int Res J. Pharm.*, vol. 2, no. 8, pp. 52-57, August 2011.
- [27] P. A. V. Devi, S. Sharmila, and S. Divyapriya, "Invitro cytotoxicity and free radical scavenging activity of aqueous extract of cucumis melo," *Int J. Pharm Biol Res.*, vol. 2, no. 6, pp. 150-156, 2011.
- [28] R. Arora, M. Kaur, and N. S. Gill, "Antioxidant activity and pharmacological evaluation of Cucumis melo var. Agrestis methanolic seed extract," *Res J. Phytochem.*, vol. 2011, pp. 1-10, 2011.
- [29] L. Mueller, and V. Boehm, "Antioxidant activity of  $\beta$ -Carotene compounds in different in vitro assays," *Molecules.*, vol. 16, pp. 1055-1069, January 2011.
- [30] J. A. Baron, B. F. Cole, L. Mott, R. Haile, *et al.*, "Neoplastic and antineoplastic effects of  $\beta$ -carotene on colorectal adenoma recurrence: Results of a randomized trial," *J. Natl Cancer Inst.*, vol. 95, pp. 717-22, May 2003.
- [31] Y. Cui, Z. Lu, L. Bai, Z. Shi, W. Zhao, and B. Zhao, " $\beta$ -Carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor  $\gamma$  expression and reactive oxygen species production in MCF-7 cancer cells," *Eur J. Cancer.*, vol. 43, no. 17, pp. 2590-2601, May 2007.
- [32] N. F. Gloria, N. Soares, C. Brand, F. L. Oliveira, R. Borojevic, and A. J. Teodoro, "Lycopene and beta-carotene induce cell-cycle arrest and apoptosis in human breast cancer cell lines," *Anticancer Res.*, vol. 34, no. 3, pp. 1377-1386, March 2014.
- [33] P. Palozza, D. Bellovino, R. Simone, A. Boninsegna, *et al.*, "Effect of beta-carotene-rich tomato lycopene beta-cyclase (tly-b) on cell growth inhibition in HT-29 colon adenocarcinoma cells," *Br J. Nutr.*, vol. 102, pp. 207-214, July 2009.
- [34] C. M. Yang, Y. T. Yen, C. S. Huang, and M. L. Hu, "Growth inhibitory efficacy of lycopene and  $\beta$ -carotene against androgen-independent prostate tumor cells xenografted in nude mice," *Mol Nutr Food Res.*, vol. 55, pp. 606-612, April 2011.
- [35] N. F. Haddad, A. J. Teodoro, F. L. de Oliveira, N. Soares, *et al.*, "Lycopene and beta-carotene induce growth inhibition and proapoptotic effects on ACTH-secreting pituitary adenoma cells," *Plos One.*, vol. 8, no. 5, pp. 1-5, March 2013.
- [36] T. M. Vogt, S. T. Mayne, B. I. Graubard, C. A. Swanson, *et al.*, "Serum lycopene, other serum carotenoids, and risk of prostate cancer in US blacks and whites," *Am J. Epidemiol.*, vol. 155, pp. 1023-1032, June 2002.
- [37] S. P. Itiyavirah and S. Cheriyan, "Evaluation of ethanolic extract of cucumis melo L. for inflammation and hyperplasia of prostate," *Int J. Nut Pharmacol Neurol Dis.*, vol. 4, no. 4, pp. 224-230, December 2014.
- [38] Y. Nakamura, Y. Nakayama, H. Ando, A. Tanaka, T. Matsuo, S. Okamoto, *et al.*, "3-Methylthiopropionic acid ethyl ester, isolated from Katsura-uri (Japanese pickling melon, cucumis melo var. conomon), enhanced differentiation in human colon cancer cells," *J. Agric Food Chem.*, vol. 56, no. 9, pp. 2977-2984, May 2008.
- [39] Y. C. Hsu, M. J. Chen, and T. Y. Huang, "Inducement of mitosis delay by cucurbitacin E, a novel tetracyclic triterpene from climbing stem of cucumis melo L., through GADD45c in human brain malignant glioma (GBM) 8401 cells," *Cell Death Dis.*, vol. 5, no. 1-9, February 2014.
- [40] K. T. Chan, K. T. Li, S. L. Liu, K. H. Chu, M. Toh, and W. D. Xie, "Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562," *Cancer Lett.*, vol. 289, no. 10, pp. 46-52, March 2010.



**Widowati. Wahyu** obtained a Bachelor degree in Toxicology from Brawijaya University, Malang, Indonesia in 1984 and the master degree in Toxicology from Gadjah Mada University in 1994. She obtained doctoral degree in Toxicology from Padjadjaran University, Indonesia, in 2004. In 2013 until now, she studied at Brawijaya University, Malang, Indonesia in Faculty of Medicine majoring Biomedical.

In August 2007, She joined Faculty of Medicine, in Maranatha Christian University, Bandung, Indonesia as a lecturer and researcher. From 2009 until now She supervised several research in phytochemical screening and activity assay as antiobesity, anti diabetes, anti-cancer, anti-oxidant, and anti-inflammation. Her current research was about the potential of conditioned medium from Wharton's Jelly human mesenchymal stem cells for cancer therapy. In January 2013, She became a president director of Aretha Medika Utama, Biomolecular and Biomedical Research Center in Bandung Indonesia. Wahyu Widowati is a member Indonesia Stem Cell Association since 2009.



**Micho Widyanto. Rachma** was born in Kediri, East Java, Indonesia in 1984. He received S.Si (Bachelor of Science) in Biotechnology from Al Azhar University, Jakarta, Indonesia in 2017 and the Masterdegree Agrobiotechnology from Brawijaya University, Malang, Indonesia, in 2011.

In 2007, He joined as Research Assistant on Cell Culture Laboratory, Center for Pharmaceutical and Medical Technology, BPPT (Agency for the Assessment and Application of Technology) -Tangerang. Working on Screening of biological activities of medicinal herb extracts based on cell lines. In 2008, He joined as Internee Student on Bio-Remodeling and Gene Therapy Lab, Dept. of Life Science, Gwangju Institute of Science and Technology (GIST) - South Korea. Working on bio-remodeling and protein engineering based on cell lines. In 2011, He joined Faculty of Medicine and Faculty of Agricultural, in Brawijaya University, Malang, Indonesia as a lecturer. Micho Widyanto, M.P., Mr. Rachma, was the member of ASPI (Indonesian Stem Cell Association).



**Laksmiawati, Dian Ratih** was born in Jakarta Indonesia on June 18th, 1968. She gained a Bachelor Degree at Faculty of Pharmacy, Pancasila University Indonesia and finished her Master Degree in Biomedical Science at Faculty of Medicine University of Indonesia in 2002. Her Doctoral degree was achieved in the same program and university in 2012. In 2009, she started working in cell culture especially in stem cell culture. She is a lecturer at Pancasila University in Biochemistry and Immunology Field and she is interest in natural product. Hence, her topic research are about immunosuppression effects of mesenchymal stem cells, the effect of Beta-carotene on proliferation and differentiation of adipose-derived stem cells into endothelial progenitor cells, antioxidant effect of Cucumis melo in culture media. Dr. Laksmiawati is a member Indonesia Stem Cell Association since 2009.



**Erawijantari, Pande Putu** was born in Tabanan, Bali, Indonesia in 1992. She received the S.Si (Bachelor of Science) degree in Biology from Institut Teknologi Bandung (Bandung Institute of Technology), Bandung, Indonesia in 2014.

In November 2014 she joined Aretha Medika Utama, Biomolecular and Biomedic Research Center in Bandung, Indonesia. Before joined Aretha Medika Utama, she involved in ITB\_Indonesia team for International Genetically Engineered Machine (iGEM) competition and won the gold medal for the "Whole cell biocatalyst for PET plastic degradation using *E. coli*" research project.

**Wijaya, Laura** obtained her Bachelor degree in Biotechnology from Atmajaya Catholic University, Jakarta, Indonesia in 2007. She started

her career as research assistant at Stem Cell and Cancer Institute, Jakarta, Indonesia in 2009. She started her working in stem cell culture.



**Dr Ferry Sandra** obtained his DDS from University of Indonesia in 1996 and PhD from Kyushu University in 2001. Then he pursued postdoctoral training in Kyushu University and Harvard Medical School. In addition, he took certification in project management. His passion in research has led him being exposed to the following research area: oncology, stem cell biology, signal transduction, herbal medicine, regenerative medicine and medical

biotechnology.

During his working career, he served several positions including Chairman of Indonesian Stem Cell Association; Steering Committee of Medical Research Unit of University of Indonesia; Head of Laboratory of Institute of Human Virology and Cancer Biology, University of Indonesia; Senior Research Advisor of Kalbe Pharmaceutical Company; Director of Stem Cell and Cancer Institute; Board of Indonesian Biotechnology Consortium.

His current assignments are also numerous, including Advisor of Indonesian Medical Society for Herbal Medicine; Advisor of Biological Collaborative Research & Education Laboratory, Trisakti University; Expert of Indonesian Society for Cancer Chemoprevention; Research Head of Indonesian Society of Oral and Maxillofacial Pathologists; Organization Head of the Indonesian Association for the Study of Medicinals; Senior Executive Editor of the Indonesian Biomedical Journal; Assistant President Director of Prodia Group.

In order to develop biomedical science in Indonesia, together with his colleagues, he established some research institutes at both academic and industrial sites. In summary, he gave lectures as an invited speaker at more than 130 seminars, published more than 60 scientific articles/books and supervised 25 postgraduate students.